Morgan Stanley Maintains Overweight Rating on Mirum Pharmaceuticals
Morgan Stanley raised its price target to $152 per share from $137 while maintaining its Overweight rating.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.